Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imarikiren Dose-finding in T2DM with Microalbuminuria
NCT02332824Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of imarikiren in diabetic nephropathy (DN) (6 arms), sponsored by Takeda. Primary endpoint: Change From End of Pre-treatment Period in Log-transformed Urine Albumin/Creatinine Ratio at Week 12. Started Oct 2014; status: completed.
02
Drugs
imarikiren
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02332824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332824.